Clinical trials: Fat; Liver
MASLD, Type 2 Diabetes
High Fructose Diet, the Gut Microbiome, and Metabolic Health
Americans commonly consume excess amounts of dietary fructose. Added fructose has been shown to have an adverse impact on metabolic health, including increased insulin resistance and type 2 diabetes (T2D) risk.
- Conditions
- MASLD, Type 2 Diabetes, Obesity
- Trial name
- NCT06329544
- Testing
- Fructose, glucose
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Icahn School of Medicine at Mount Sinai
Cardiovascular Diseases, Non-Alcoholic Fatty Liver Disease
Smart Watch Insights for Prevention of Exacerbations and Enhance Rehabilitation - Movement Study
Aims of the study: 1. To deliver a scalable wellbeing programme to the local population of Imperial College Healthcare NHS Trust, focusing on movement. 2.
- Conditions
- Cardiovascular Diseases, Non-Alcoholic Fatty Liver Disease, Respiratory Disease, Diabetes
- Trial name
- SWIPER-MOVES (NCT06011356)
- Testing
- Smartwatch
- Where
- United Kingdom
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Imperial College London
NAFLD
Genetic-specific Effects of Fructose on Liver Lipogenesis
The primary goal of this study is to identify a set of genotypes that increase the risk for nonalcoholic fatty liver disease (NAFLD) and predispose individuals to increased de novo lipogenesis (DNL) and liver fat accumulation…
- Trial name
- NCT03783195
- Testing
- Sugar drink
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Fatty Liver, Liver Diseases
Long-term Follow Up of Patients in the Birmingham and Lambeth Liver Evaluation Strategies (BALLETS) Study
This study will follow-up a cohort of patients from the Birmingham and Lambeth Liver Evaluation Strategies (BALLETS) study using a database search based on their individual National Health Service (NHS) numbers.
- Trial name
- NCT04022681
- Testing
- BALLETS
- Volunteers
- 1,237 people
- Sponsor
- University of Warwick
Nonalcoholic Fatty Liver Disease
Role of Pioglitazone and Berberine in Treatment of Non-Alcoholic Fatty Liver Disease
The purpose of this study is to evaluate the effects and safety of pioglitazone and berberine on the basis of lifestyle intervention to non-alcoholic fatty liver disease patients with impaired glucose regulation or type 2…
- Trial name
- NCT00633282
- Testing
- Life style intervention, pioglitazone, berberine
- Where
- 3 sites in China
- Volunteers
- 184 people
- Sponsor
- Xin Gao
Overweight and/or Obesity, Metabolic Syndrome
iWAIST Trial: ERCG (Endoscopic Radial Compression Gastroplasty) +Optimized Lifestyle Intervention (OLI) vs Sham + OLI for Weight Loss
This randomized, sham-controlled trial evaluates the efficacy and safety of ERCG plus optimized lifestyle intervention compared with sham procedure plus optimized lifestyle intervention in Chinese adults with overweight…
- Conditions
- Overweight and/or Obesity, Metabolic Syndrome, Nonalcoholic Fatty Liver Disease
- Trial name
- iWAIST-RCT (NCT07237750)
- Testing
- Endoscopic Radial Compression Gastroplasty, Optimized Lifestyle Intervention (OLI)
- Where
- 2 sites in China
- Volunteers
- 216 people
- Sponsor
- Liu Yan
Obesity
Short-term Investigation of Resveratrol on Fat Metabolism in Morbidly Obese Women Undergoing Gastric Bypass Surgery
The purpose of this study is to investigate potential metabolic effects of resveratrol in morbidly obese women undergoing gastric bypass surgery.
- Trial name
- NCT01826279
- Testing
- Resveratrol
- Where
- Denmark
- Volunteers
- 16 people
- Sponsor
- University of Aarhus
Type 2 Diabetes
Longitudinal Assessment of Multiple Organs in Patients With Type 2 Diabetes
MODIFY study is a multi-centre prospective, longitudinal, observational cohort study which aims to recruit 150 adult patients with type 2 diabetes recruited from community, primary care or secondary care settings.
- Trial name
- MODIFY (NCT04114682)
- Testing
- Multi parametric MRI scan
- Where
- 4 sites in United Kingdom
- Volunteers
- 135 people
- Sponsor
- Perspectum
NASH, HCC
Evaluation of Risk of hEpatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the fifth most common solid cancer and the second cause of cancer-related mortality worldwide.
- Conditions
- NASH, HCC, Genetic Predisposition
- Trial name
- PERSPECTIVE (NCT06523179)
- Testing
- quantify the impact of genetic risk factors
- Where
- Italy
- Volunteers
- 500 people
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Non-alcoholic Fatty Liver Disease
Hepar-P Study to Evaluate the Safety and Efficacy of a Standardised Extract of Phyllanthus Niruri for the Treatment of Non-alcoholic Fatty Liver Disease
This is a multi-center, double blind, parallel group placebo controlled randomised trial designed to determine the safety and efficacy of a Standardised Extract of Phyllanthus Niruri (EPN 797) HEPAR-P capsule for the treatment of…
- Trial name
- Hepar-P (NCT01680003)
- Testing
- Hepar-P
- Where
- 5 sites in Malaysia
- Volunteers
- 50 people
- Sponsor
- Nova Laboratories Sdn Bhd
Non-Alcoholic Fatty Liver Disease
Evaluation of Lipid Profile in Different Grades of Non-alcoholic Fatty Liver Disease Diagnosed by Ultrasound
Liver cells play a major role in the regulation of lipid metabolism. They are the principal location for lipoprotein and cholesterol synthesis.
- Trial name
- NCT05486429
- Testing
- Abdominal ultrasound and lipid profile
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Sohag University
NAFLD
Short and Long Term Clinical and Patient-Reported Outcomes Associated With Intragastric Balloon Placement in Patients With Nonalcoholic Fatty Liver Disease
This study aims to enroll a robust cohort of NAFLD patients who undergo Intragastric Balloon placement through a multidisciplinary program approach to evaluate clinical and patient-reported outcomes for at least one-year…
- Trial name
- NCT07493967
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Methodist Health System
Metabolic Dysfunction-Associated Steatotic Liver Disease, Non-alcoholic Fatty Liver Disease
Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (MK-6024-016)
This study will evaluate the effect of efinopegdutide administration once every 2 weeks (Q2W) versus once weekly (Q1W) on mean relative reduction from baseline in liver fat content (LFC) after 28 weeks, as well as the safety and…
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease, Non-alcoholic Fatty Liver Disease, Nonalcoholic Fatty Liver Disease, Liver Disease
- Trial name
- NCT06482112
- Testing
- Efinopegdutide
- Where
- 39 sites in United States, Puerto Rico
- Volunteers
- 124 people
- Sponsor
- Merck Sharp & Dohme LLC
Non Alcoholic Fatty Liver Disease, Non Alcoholic Steatohepatitis
Glucose-induced Glucagon-like Peptide 1 (GLP-1) Secretion in NAFLD Patients Compared to Healthy Controls
The incretin effect is impaired in patients with type 2 diabetes mellitus (T2DM), thus GLP-1 receptor agonists are used for the treatment of T2DM.
- Trial name
- NCT01674972
- Testing
- Oral glucose tolerance test
- Where
- Switzerland
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
NAFLD, Type 2 Diabetes
Postprandial VLDL-triglyceride Metabolism in Type 2 Diabetes Patients With and Without NAFLD
Non-alcoholic fatty liver disease (NAFLD) covers a spectrum from simple reversible hepatic steatosis to inflammation and fibrosis termed steatohepatitis (NASH).
- Trial name
- NCT05044130
- Testing
- High-fat mixed-meal tolerance test (HF-MMTT)
- Where
- Denmark
- Volunteers
- 17 people
- Sponsor
- University of Aarhus
Type 2 Diabetes, Prediabetes
Seum Bile Acid Profile in Type 2 Diabetes and Association Between Bile Cid Profile and Adipokine or Oxidative Stress
"The goal of this work is to critically test the hypothesis that there exists a different profile of bile acids (BAs) in patient with type 2 diabetes mellitus (T2DM) compared with normal controls.
- Conditions
- Type 2 Diabetes, Prediabetes, Non-alcoholic Fatty Liver Disease, Metabolic Syndrome
- Trial name
- NCT02650830
- Where
- South Korea
- Volunteers
- 362 people, healthy volunteers welcome
- Sponsor
- Yonsei University
Psoriasis, Fatty Liver
Lifestyle Modification in Psoriatic Patients With Fatty Liver
Several recent reports have shown an increased prevalence of nonalcoholic fatty liver disease (NAFLD) in those with psoriasis, which may reflect the increased occurrence of metabolic syndrome in this patient population.
- Trial name
- NCT05125757
- Testing
- lifestyle modification, usual lifestyle
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Cairo University
Fatty Liver
Omega 3 Supplementation in Fatty Liver
Nonalcoholic fatty liver disease (NAFLD) is a clinical and pathological condition, whose spectrum can range from steatosis to steatohepatitis and cirrhosis, in patients without a history of alcohol abuse.
- Trial name
- OMEGA 3 NASH (NCT01992809)
- Testing
- Omega 3
- Where
- Brazil
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of Sao Paulo General Hospital
NASH - Nonalcoholic Steatohepatitis
A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis
A double-blind placebo controlled randomized Phase 3 study to determine if 80 or 100 mg of MGL-3196 as compared with placebo resolves NASH and/or reduces fibrosis on liver biopsy and prevents progression to cirrhosis and/or…
- Trial name
- MAESTRO-NASH (NCT03900429)
- Testing
- MGL-3196, Liver Biopsy
- Where
- 247 sites in United States, Australia and 14 more
- Volunteers
- 1,759 people
- Sponsor
- Madrigal Pharmaceuticals, Inc.
Non-alcoholic Fatty Liver Disease
Efficacy of a Natural Components Mixture in the Treatment of Non Alcoholic Fatty Liver Disease (NAFLD)
The objective of this study is to provide clinical data to support the effectiveness of a mixture of ingredients of natural origin, suitably selected and packaged, in the protection from liver damage, in subjects with NAFLD.
- Trial name
- NUTRAFAST (NCT02369536)
- Testing
- nutraceutical mixture
- Where
- Italy
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Neuromed IRCCS
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.